Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 12-Month High – What’s Next?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) hit a new 52-week high on Friday . The company traded as high as $33.23 and last traded at $31.8550, with a volume of 240600 shares trading hands. The stock had previously closed at $30.75.

Analyst Ratings Changes

Separately, UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Chugai Pharmaceutical has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Price Performance

The business’s 50-day moving average price is $27.54 and its 200-day moving average price is $24.97. The firm has a market capitalization of $105.35 billion, a PE ratio of 36.79 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.The firm had revenue of $2.25 billion for the quarter. Equities analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.